BEACH Trial: Bovine Early Access, Compatibility and Hemostasis Trial
Study Details
Study Description
Brief Summary
Bovine Early Access, Compatibility, and Hemostasis (BEACH) Trial Study is to evaluate the Safety and Effectiveness of Early Access in Patients Who Require an Arteriovenous Conduit for Hemodialysis using the Artegraft® Collagen Vascular Graft™. The objective of the BEACH Trial is to demonstrate that early access of Artegraft is associated with acceptable rates of successful early access, and acceptable rates of a composite of adverse events, to support a modification of existing device labeling stating that Artegraft is capable of cannulation within 72 hours post implantation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Chronic kidney disease (CKD) is a major health problem that affects approximately 26 million Americans. Many of those suffering CKD will progress to develop end stage renal disease (ESRD) and require lifelong hemodialysis (HD) to filter wastes from their blood. There are nearly 2.5 million patients who receive HD worldwide, and this population is growing at a rate of 8% per year. This projects that the worldwide HD population to reach approximately 3.4 million by the year 2020. There are over 600,000 patients on HD in the US and an estimated 100,000 new cases are reported annually. The interventions required to maintain a person on HD carry a significant financial burden, with costs estimated to be as high as $30 billion annually. Given the increasing epidemic of obesity, diabetes, and heart disease, the burden of ESRD will continue to grow, making new interventions that can improve the social, physical, and financial realities of treating ESRD essential.
A critical factor in the survival of renal dialysis patients is the surgical creation of vascular access. Despite the fistula-first initiative, many patients will start hemodialysis using a central venous catheter (CVC). This increases the risks of associated bloodstream infections, central venous stenosis, and poorer outcomes from subsequent vascular cannulations.
Arteriovenous grafts have advantages compared with central venous catheters for dialysis and guidelines suggest their use as second choice after arteriovenous fistulas. The suggested advantages of grafts over fistulas is the ability to cannulate or access the graft earlier, traditionally 2 weeks for AVG rather than 6 weeks for AVF, and the lower rates of primary failure.
Standard practice with expanded polytetrafluoroethylene (ePTFE) grafts has been to avoid cannulation for 2 weeks following placement, but new generation grafts have been marketed for their early cannulation properties allowing use as an alternative to central venous catheters for prompt access.
The proposed BEACH Trial is a multi-center, prospective clinical trial to evaluate early access of an existing, FDA-approved bovine carotid vascular graft, approved as a general peripheral vascular graft and for hemodialysis. The BEACH Trial is seeking to demonstrate that early access, defined as within 72 hours post implantation, of the Artegraft device results in acceptable clinical outcomes including ability to support dialysis needs thereby obviating the requirement for interim catheter placement or facilitating the removal of an existing catheter with acceptable composite major adverse clinical events (MACE) rate up to 26 weeks (6 months) post implant.
Few vascular products approved in the 1970s have a broad level of acceptance in today's competitive market. Review of the original NDA application for Artegraft as well as the scientific literature revealed no clinical rationale for a waiting period of 14 days (for most access grafts) and 10 days (for Artegraft) before cannulation. The current literature does not seem to support the current guidelines as there is no evidence to suggest that a delay in cannulation of PTFE grafts will improve graft survival and patency.Note also that Artegraft cannot identify any scientific justification in the original NDA for the warning that was placed in the IFU to support the 10-day waiting period before cannulation.
Further, if it is assumed that dialysis is conducted 3 times per week, by allowing cannulation to the Artegraft device in the 72-hour period, only 6 to 10 additional needle punctures are added during the first 10-day period depending on whether cannulation is initiated within 72 hours, respectively. Artegraft believes that this limited number of additional early needle punctures will not significantly affect the safety or efficacy of the graft or the cannulation procedure.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Early Access Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed in less than 72 hours after implantation. |
Device: Artegraft® Collagen Vascular Graft™ (Artegraft)
The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
|
| Active Comparator: Normal Access Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed after 10 days as per current IFU. |
Device: Artegraft® Collagen Vascular Graft™ (Artegraft)
The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
|
Outcome Measures
Primary Outcome Measures
- Primary Effectiveness Endpoint (Early access success) [less than 72 hours]
Early access success, defined by three cannulations, the first one started within 72 hours after implantation, all with minimum dialysis flow rates of 250 ml/min pump flow rate, with a minimum 17-gauge needle.
- Primary Safety Endpoint (composite of major adverse clinical events) [Less than 6 month]
A composite of major adverse clinical events (MACE) including perigraft infection, hemorrhage / hematoma, thrombosis, and pseudoaneurysm within 30 days after first cannulation [Day 0] in the early-access and late-access groups.
Secondary Outcome Measures
- Secondary Effectiveness Endpoints (Patency) [Less than 6 months]
Patency (Primary, Assisted Primary, and Secondary) at 30 days after first successful cannulation [Day 0], and at 12 and 6 months after implantation in the early-access group and at 30 days post-Day 0 in the late-access group. The late access group will also be assessed for patency at 6 months through a telephone interview or office visit to provide a more robust data set.
- Secondary Safety Endpoint (for information only) adverse events [Less than 6 months]
All adverse events will be collected in the early-access group [to 6 months] and the late-access group [to 30 days post Day 0] and summarized by unique event, seriousness, and relationship to device or procedure.
- Secondary Catheter Removal Endpoint (For information only) [Less than 6 months]
The number of days from graft implant or fistula revision to catheter removal shall be recorded.
Eligibility Criteria
Criteria
Inclusion Criteria:
Patients are eligible to be included in the study only if they meet the following criteria:
-
Male or Female, 18 years or older
-
Diagnosis of End Stage Renal Disease (ESRD) and require vascular access for hemodialysis
-
Native [autogenous tissue] AV fistula creation or access is not indicated or non-viable [disadvantaged veins]
-
Requiring repair of an existing fistula or conduit, but only if using Artegraft as an interposition placement and the Artegraft is cannulated [not the fistula]. Artegraft must be place in a fresh subcutaneous tunnel. Thigh loop grafts will not be used.
-
Able to accommodate vascular graft placement in the upper extremity (i.e., forearm, or upper arm)
-
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)
-
Able and willing to comply with the study protocol
-
Agrees to initiate and maintain hemodialysis treatments
-
Life expectancy is > 1 year based on physician assessment
Exclusion Criteria:
Patients are excluded from the trial if any of the following criteria apply:
-
High grade central venous stenosis/occlusion
-
Breast-feeding, pregnant or planning pregnancy within next 12 months.
-
Non-resolved infected existing grafts
-
Documented sepsis/bacteremia by blood culture within 4 weeks of implantation.
-
History of non-controlled immunodeficiency syndrome, including AIDS/HIV; Active clinically significant immune-mediated disease, not controlled by low-dose maintenance immunosuppression. The diagnosis of HIV alone, provided adequately treated, is not a contraindication for enrolment.
-
Severe liver dysfunction and/or coagulation or bleeding disorders.
-
Elevated platelet count > 1 million cells/mm3
-
History of heparin-induced thrombocytopenia syndrome (HIT)
-
Documented hypercoagulable state
-
Currently participating in another investigational drug or device study which may clinically interfere with any endpoints of this trial
-
Known hypersensitivity or contraindication to device materials or procedural medications that cannot be adequately managed medically
-
History or evidence of severe cardiac disease (NYHA Functional Class III or IV), , myocardial infarction within 6 months of enrollment, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina, uncontrolled CHF
-
History or evidence of severe peripheral arterial disease in the extremity selected for implant (i.e. arterial inflow insufficient to support hemodialysis)
-
History of cancer with active disease or treatment within the previous year, except for non-invasive basal or squamous cell carcinoma of the skin
-
Bleeding diathesis, other than that associated with ESRD
-
Scheduled renal transplant within 6 months
-
Patients who require chronic anticoagulation except for antiplatelet therapy. Patients currently receiving or who have received within the last month direct thrombin inhibitors, factor Xa inhibitors, or vitamin K antagonists should not be included in the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of California | San Diego | California | United States | 92093 |
| 2 | Capital District Renal Physicians | Albany | New York | United States | 12209 |
| 3 | Dialysis Access Institute | Orangeburg | South Carolina | United States | 29118 |
| 4 | Spartanburg Regional Medical Center | Spartanburg | South Carolina | United States | 29303 |
| 5 | City Hospital at White Rock | Dallas | Texas | United States | 75218 |
Sponsors and Collaborators
- Artegraft, Inc.
Investigators
- Principal Investigator: Mahmoud Malas, MD, University of California, San Diego
Study Documents (Full-Text)
None provided.More Information
Publications
- Fresenius Medical Care : Fresenious Medical Care Annual Report 2011 - Dialysis Market, Bad Homburg, Germany, Freesenious Medical Care, 2011
- US Renal Data System: 2012 Annual Data Report : Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012
- US Renal Data System: 2014 Annual Data Report : Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2014
- ARTCT.BEACH.001